Figure 4. Knockdown of any of several key SWI/SNF subunits sensitizes human pancreatic ductal epithelial cells to oxaliplatin.

(A) siRNA knockdown of SMARCA2, ARID1A and ARID1B in HPDE cells, confirmed by western blot, compared to non-targeting control (NTC); GAPDH serves as a loading control. (B) Bar graph summarizing fold-reductions in IC₅₀ with knockdown of SMARCA4 (from Figure 1D), SMARCA2, ARID1A, and ARID1B (vs. NTC), for oxaliplatin. (C–E) Dose-response curves comparing HPDE cell viability following knockdown of (C) SMARCA2, (D) ARID1A, and (E) ARID1B (vs. NTC), for oxaliplatin. IC₅₀ values indicated.